Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$75.25M+240709.60%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher R. Anzalone
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 711
- Beta
- 1.30
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.74
Financials
Revenue
$75.25M+240709.6%Net Income
$-194.28MEBITDA
$-147.68MFree Cash Flow
$-181.32MEPS (diluted)
$-1.36Shares Outstanding (diluted)
143.38M+100.7%Operating Expenses
$245.35MCash & Debt
$1.60BReturn of Capital
$38.43MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $829.45M | $-1.63M | $-0.01 |
| 2024 | $3.55M | $-599.49M | $-5.00 |
| 2023 | $240.74M | $-205.28M | $-1.92 |
| 2022 | $243.23M | $-176.06M | $-1.67 |
| 2021 | $138.29M | $-140.85M | $-1.36 |
| 2020 | $87.99M | $-84.55M | $-0.84 |
| 2019 | $168.80M | $67.97M | $0.72 |
| 2018 | $16.14M | $-54.45M | $-0.65 |
| 2017 | $31.41M | $-34.38M | $-0.47 |
| 2016 | $158.3K | $-81.72M | $-1.34 |
| 2015 | $382.0K | $-91.94M | $-1.60 |
| 2014 | $175.0K | $-58.63M | $-1.25 |
| 2013 | $290.3K | $-31.14M | $-1.30 |
| 2012 | $146.9K | $-21.13M | $-1.90 |
Valuation
ARWRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (20)
- News (RSS)seekingalpha·5d ago·Positive
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher
View source ↗ - Newsseekingalpha.com·5d ago·Neutral
…armaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) with plozasiran, leveraging a faster launch via a $215M priority review voucher. ARWR's SHASTA-3 and SHASTA-4 Phase III data show plozasiran achieves 79–81% median triglyceride reductions and favorable safety, with quarterly dosing and no liver fat or thrombocytopenia signals. Current financials reflect partner-driven revenue and a strategic buildout for sHTG; liquidity of ~$1.35B post-voucher supports operation…
View source ↗ - News (RSS)financialpost·15d ago·Neutral
One year in, Arrowhead Intermediaries advances integration with brand alignment Three focused divisions, one unified platform — Arrowhead marks a year of new products, AI advancement and operational integration, and outlines a simplified customer experience beginning in 2027 SAN DIEGO, Sept. 22, 2026 (GLOBE NEWSWIRE) — Arrowhead Intermediaries (Arrowhead), a global insurance distribution platform, marked one year since the acquisition of One80 Intermediaries and the […]
View source ↗ - News (RSS)businessinsider·15d ago·Neutral
One year in, Arrowhead Intermediaries advances integration with brand alignment <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="left">SAN DIEGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=qcrYQaNjVhA0ZMcnJx6XrlsE-09msUmL-DiZHqFURBIHAukTSScUht87qjxzB2eJT9e9WbvS0gJbpVVI7PKap8UXxZmCM9KzrDy3DGXEK4XUQ6jVO11xiD7xoGt7tUM4"...
View source ↗ - Newsmarketbeat.com·19d ago·Negative
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders.
View source ↗ - Newsseekingalpha.com·22d ago·Positive
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
View source ↗ - Newsseekingalpha.com·23d ago·Positive
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)economictimes·24d ago·Neutral
Voice AI startup Arrowhead eyes fresh funding
View source ↗ - Newsseekingalpha.com·28d ago·Positive
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - News (RSS)fool·31d ago·Negative
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million Perry's liquidity event comes as the Arrowhead stock price surged.
View source ↗ - Newsfool.com·31d ago·Negative
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million The transaction was valued at $1 million. The sale reduced the director's direct equity holdings by 9%.
View source ↗ - News (RSS)seekingalpha·35d ago·Neutral
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia - Slideshow
View source ↗ - News (RSS)seekingalpha·35d ago·Neutral
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at European Society of Cardiology (ESC) Congress 2026 - Slideshow
View source ↗ - Newsseekingalpha.com·37d ago·Positive
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript
View source ↗ - Newsmarketbeat.com·38d ago·Negative
Arrowhead's Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials Arrowhead Pharmaceuticals NASDAQ: ARWR presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycerides and acute pancreatitis events versus placebo. The company said the data were presented at the European Society of Cardiology Congress in Munich and have been accepted for publication in a major…
View source ↗ - News (RSS)investing·38d ago·Neutral
Arrowhead plans regulatory filing for plozasiran in sHTG
View source ↗ - Newsgurufocus.com·39d ago·Negative
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with sever
View source ↗ - Newsbusinesswire.com·39d ago·Negative
…Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia PASADENA, Calif.--(BUSINESS WIRE)-- #arrowheadpharma--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a Hot Line Late-Breaking Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. SHASTA-3 and SHASTA-4 met their primary and all prespecifie…
View source ↗ - Newsprnewswire.com·41d ago·Neutral
Mercedes-Benz of Arrowhead Offers Cars with Massage Seats /PRNewswire/ -- Mercedes-Benz of Arrowhead offers new and pre-owned Mercedes-Benz cars with massage seats. The dealership also offers other pre-owned brands
View source ↗ - Newsbusinesswire.com·45d ago·Neutral
…armaceuticals to Present New Clinical Data at the European Society of Cardiology Congress PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany. ESC 2026 Presentation Details Date & Time: Sunday, August 30, 2026, 17:30 CEST Session Title: HOT LINE 9 Late-breaking Science Session Location: Munich Auditorium-Hall B3 Title: Plozasiran in patient…
View source ↗
Earnings
Tue, Nov 24(in 7 weeks)
Consensus estimate $-1.59 per share
Typical surprise -34.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-1.36 vs $-1.28miss
- Thu, May 7$-0.93 vs $-1.09beat
- Thu, Feb 5$0.22 vs $0.60miss
- Tue, Nov 25$-0.18 vs $-0.11miss
- Thu, Aug 7$-1.26 vs $-0.94miss
- Mon, May 12$2.75 vs $-0.06beat
Estimates and results for ARWR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARWR officers and directors.
- Bought
- —
- Sold
- $39.5m
0 trades
72 trades
- Olukotun Adeoye Ysold
- Perry Michael Ssold
- Lu Hongbosold
- Hamilton James Csold
- Apel Daniel Josephsold
- Apel Daniel Josephsold
- Apel Daniel Josephsold
- Hamilton James Csold
28 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (24d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.